Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys
Version of Record online: 25 JAN 2006
Copyright © 2006 American Neurological Association
Annals of Neurology
Volume 59, Issue 2, pages 282–288, February 2006
How to Cite
Samadi, P., Grégoire, L., Rouillard, C., Bédard, P. J., Di Paolo, T. and Lévesque, D. (2006), Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. Ann Neurol., 59: 282–288. doi: 10.1002/ana.20738
- Issue online: 25 JAN 2006
- Version of Record online: 25 JAN 2006
- Manuscript Accepted: 10 OCT 2005
- Manuscript Revised: 7 SEP 2005
- Manuscript Received: 26 MAY 2005
- Canadian Institutes for Health Research. Grant Number: 200303MOP-118040
- Parkinson Society of Canada
- Parkinson's Disease Foundation of United States
The objective of the present study was to investigate the effect of docosahexaenoic acid (DHA), a polyunsaturated fatty acid (omega-3), on levodopa-induced dyskinesias (LIDs) in parkinsonian 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)–treated monkeys.
We explored the effect of DHA in two paradigms. First, a group of MPTP monkeys was primed with levodopa for several months before introducing DHA. A second group of MPTP monkeys (de novo) was exposed to DHA before levodopa therapy.
DHA administration reduced LIDs in both paradigms without alteration of the anti-parkinsonian effect of levodopa indicating that DHA can reduce the severity or delay the development of LIDs in a nonhuman primate model of Parkinson's disease.
These results suggest that DHA can reduce the severity or delay the develoment of LIDs in a nonhuman primate model of Parkinson's disease. DHA may represent a new approach to improve the quality of life of Parkinson's disease patients. Ann Neurol 2006;59:282–288